Leadership Overview
Eisai has 6 executives leading key functions including strategy, operations, scientific research, partnership management, and regional business units.
Driven by a commitment to patient well-being, Eisai focuses on developing innovative pharmaceutical solutions to address unmet medical needs globally, particularly in neurology and oncology.
Driven by a commitment to patient well-being, Eisai focuses on developing innovative pharmaceutical solutions to address unmet medical needs globally, particularly in neurology and oncology.
Leadership Roles at Eisai
Toshio Imai - President & Chief Executive Officer & Scientific Chief & Officer
Toshio Imai, the President & Chief Executive Officer & Scientific Chief & Officer at Eisai, directs the overarching corporate strategy and scientific vision. This leadership role involves guiding the company's research and development pipeline, ensuring alignment with global health priorities and market demands. Imai oversees the integration of scientific discovery with commercial execution, driving innovation in therapeutic areas such as Alzheimer's disease and oncology. The executive's focus extends to fostering a culture of scientific excellence and ethical practice across all Eisai operations. By championing groundbreaking research, Toshio Imai ensures Eisai remains at the forefront of pharmaceutical innovation, delivering critical treatments to patients worldwide and solidifying the company's market position through scientific leadership.
Shaji Procida - President & Chief Operating Officer
Shaji Procida, the President & Chief Operating Officer at Eisai, manages the day-to-day operational execution and efficiency across the organization. This critical role involves optimizing business processes, ensuring seamless integration of global operations, and driving productivity improvements. Procida oversees supply chain management, manufacturing, and the effective deployment of resources to support Eisai's product portfolio. The executive's responsibilities include enhancing operational resilience and scalability to meet growing market demands for pharmaceutical products. By streamlining operations and fostering cross-functional collaboration, Shaji Procida ensures that Eisai can reliably deliver its innovative treatments to patients, supporting the company's mission of improving global health outcomes through operational excellence.
Shawn Gallagher - President, Partnership Management Core Functional Unit
Shawn Gallagher, the President, Partnership Management Core Functional Unit at Eisai, leads the strategic development and execution of key collaborations and alliances. This role is vital for expanding Eisai's reach and therapeutic capabilities through external partnerships. Gallagher oversees the identification, negotiation, and management of strategic relationships with other pharmaceutical companies, research institutions, and biotechnology firms. The executive's focus includes fostering synergistic relationships that accelerate drug development and market access. By cultivating strong partnerships, Shawn Gallagher enhances Eisai's innovation ecosystem, enabling the company to bring more life-changing treatments to patients faster and more effectively, thereby strengthening Eisai's global impact.
Cynthia Schwalm - President
Cynthia Schwalm, the President at Eisai, drives strategic initiatives and operational oversight within designated business units. This leadership position involves guiding the development and implementation of market-specific strategies to enhance Eisai's presence and product adoption. Schwalm focuses on optimizing commercial performance, ensuring alignment with the company's global mission and therapeutic priorities. The executive's responsibilities include fostering strong relationships with healthcare providers and stakeholders to advance patient care. By leading key business functions, Cynthia Schwalm contributes significantly to Eisai's growth and its ability to deliver innovative pharmaceutical solutions that address critical health challenges worldwide.
Michael De - President, Eisai Machinery (USA)
Michael De, the President, Eisai Machinery (USA), directs the operations and strategic direction of the company's machinery division within the United States. This role is essential for supporting Eisai's pharmaceutical manufacturing capabilities and ensuring the efficient production of vital medicines. De oversees the technological advancements and operational efficiency of Eisai Machinery, focusing on innovation in manufacturing equipment and processes. The executive's leadership ensures that the machinery division meets the stringent quality and regulatory standards required in the pharmaceutical industry. By driving excellence in manufacturing technology, Michael De supports Eisai's broader mission of providing high-quality pharmaceutical products to patients across the globe.
Kenichi Nomoto - Chief Scientific Officer
Kenichi Nomoto, the Chief Scientific Officer at Eisai, spearheads the company's scientific research and discovery efforts. This position involves identifying and advancing novel therapeutic targets, particularly in neurology and oncology, aligning with Eisai's core therapeutic areas. Nomoto directs the scientific strategy for drug development, from early-stage research through to clinical validation. The executive's work is crucial in translating scientific insights into potential treatments for debilitating diseases. By fostering innovation and collaboration within the scientific community, Kenichi Nomoto ensures Eisai's research pipeline remains robust and addresses significant unmet medical needs, driving the company's commitment to patient well-being through cutting-edge science.
Explore Leadership Teams in Manufacturing
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life. AbbVies scientific and commercial efforts are concentrated in several core therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics, along with other specialty areas where significant unmet medical needs exist. Through these focus areas, the company works to create therapies that help patients manage chronic, serious, and often life-altering diseases.
Company Leadership XY
CL
NR
MS
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
Company Leadership
CA
SH
ST
Alvogen, founded in 2009 headquartered in Morristown, New Jersey, operates as a pharmaceutical company. The Company develops, manufactures, and markets parallel imported and generic drugs. Alvogen Pharma US serves clients worldwide.
Company Leadership SP
NB
JJ
JL
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Companys range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
Company Leadership FJ
Frequently Asked Questions Regarding Eisai Top Executives and Leadership Team
